{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:51:25Z","timestamp":1790675485766,"version":"4.1.0"},"reference-count":172,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Antifungal therapy for pulmonary fungal diseases is in a state of flux. Amphotericin B, the time-honored standard of care for many years, has been replaced by agents demonstrating superior efficacy and safety, including extended-spectrum triazoles and liposomal amphotericin B. Voriconazole, which became the treatment of choice for most pulmonary mold diseases, has been compared with posaconazole and itraconazole, both of which have shown clinical efficacy similar to that of voriconazole, with fewer adverse events. With the worldwide expansion of azole-resistant Aspergillus fumigatus and infections with intrinsically resistant non-Aspergillus molds, the need for newer antifungals with novel mechanisms of action becomes ever more pressing.<\/jats:p>","DOI":"10.3390\/jof9020144","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T02:01:02Z","timestamp":1674439262000},"page":"144","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Systemic Antifungal Therapy for Invasive Pulmonary Infections"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0628-0798","authenticated-orcid":false,"given":"Ronen","family":"Ben-Ami","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Bongomin, F., Gago, S., Oladele, R.O., and Denning, D.W. (2017). Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J. Fungi, 3.","DOI":"10.3390\/jof3040057"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"ofy187","DOI":"10.1093\/ofid\/ofy187","article-title":"Epidemiology and Clinical Features of Invasive Fungal Infection in a US Health Care Network","volume":"5","author":"Webb","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Nnadi, N.E., and Carter, D.A. (2021). Climate change and the emergence of fungal pathogens. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1009503"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s11046-020-00431-2","article-title":"Re-drawing the Maps for Endemic Mycoses","volume":"185","author":"Ashraf","year":"2020","journal-title":"Mycopathologia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","article-title":"Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications","volume":"30","author":"Nett","year":"2016","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: A phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus","volume":"21","author":"Arendrup","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Snelders, E., van der Lee, H.A., Kuijpers, J., Rijs, A.J., Varga, J., Samson, R.A., Mellado, E., Donders, A.R., Melchers, W.J., and Verweij, P.E. (2008). Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med., 5.","DOI":"10.4016\/8254.01"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dkx028","article-title":"Changes in the epidemiological landscape of invasive mould infections and disease","volume":"72","author":"Cornelia","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_15","first-page":"1621","article-title":"Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions","volume":"67","author":"Lionakis","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"a019653","DOI":"10.1101\/cshperspect.a019653","article-title":"Antifungal pharmacokinetics and pharmacodynamics","volume":"5","author":"Lepak","year":"2014","journal-title":"Cold Spring Harb. Perspect Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.coph.2007.05.004","article-title":"Pharmacodynamic implications for use of antifungal agents","volume":"7","author":"Lewis","year":"2007","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S2352-3026(21)00232-5","article-title":"Management of drug\u2013drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs","volume":"9","author":"Verheggen","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Bruggemann","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1128\/AAC.34.10.2032","article-title":"Effect of oral antacid administration on the pharmacokinetics of oral fluconazole","volume":"34","author":"Thorpe","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF00199879","article-title":"Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole","volume":"46","author":"Zimmermann","year":"1994","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1093\/ndt\/gfg363","article-title":"Dosing guidelines for fluconazole in patients with renal failure","volume":"18","author":"Cousin","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"354","DOI":"10.7326\/0003-4819-123-5-199509010-00006","article-title":"Alopecia associated with fluconazole therapy","volume":"123","author":"Pappas","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/17425255.2019.1671971","article-title":"Therapeutic drug monitoring of systemic antifungal agents: A pragmatic approach for adult and pediatric patients","volume":"15","author":"John","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1093\/cid\/ciw360","article-title":"2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis","volume":"63","author":"Galgiani","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1086\/595687","article-title":"Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis","volume":"48","author":"Ampel","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3201\/eid2006.131842","article-title":"Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis","volume":"20","author":"Blair","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"676","DOI":"10.7326\/0003-4819-133-9-200011070-00009","article-title":"Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group","volume":"133","author":"Galgiani","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"ref_30","unstructured":"Food and Drug Administration (2023, January 18). Sporanox (Itraconazole). Full Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020083s040s041s044lbl.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1128\/AAC.36.2.477","article-title":"Effect of cyclodextrin on the pharmacology of antifungal oral azoles","volume":"36","author":"Hostetler","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1439-0507.1989.tb02296.x","article-title":"The clinical pharmacokinetics of itraconazole: An overview","volume":"32","author":"Heykants","year":"1989","journal-title":"Mycoses"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.cmi.2020.06.007","article-title":"How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)","volume":"26","author":"Arendrup","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/14787210.2016.1199272","article-title":"Antifungal agents and liver toxicity: A complex interaction","volume":"14","author":"Tverdek","year":"2016","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1128\/AAC.01657-09","article-title":"Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection","volume":"54","author":"Wang","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2003-07-2512","article-title":"Cyclophosphamide metabolism is affected by azole antifungals","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/AAC.35.4.707","article-title":"High-dose itraconazole in the treatment of severe mycoses","volume":"35","author":"Sharkey","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/myc.12749","article-title":"Itraconazole induced hypertension and hypokalemia: Mechanistic evaluation","volume":"61","author":"Hoffmann","year":"2018","journal-title":"Mycoses"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.mayocpiqo.2020.05.006","article-title":"The Many Faces of Itraconazole Cardiac Toxicity","volume":"4","author":"Teaford","year":"2020","journal-title":"Mayo Clin. Proc. Innov. Qual Outcomes"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM200003163421102","article-title":"A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis","volume":"342","author":"Stevens","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1439-0507.1988.tb03653.x","article-title":"The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987)","volume":"31","author":"Cauwenbergh","year":"1988","journal-title":"Mycoses"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/myc.12075","article-title":"Itraconazole in chronic cavitary pulmonary aspergillosis: A randomised controlled trial and systematic review of literature","volume":"56","author":"Agarwal","year":"2013","journal-title":"Mycoses"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1001\/archinte.1997.00440370097010","article-title":"Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria","volume":"157","author":"Stevens","year":"1997","journal-title":"Arch. Intern. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1086\/521259","article-title":"Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America","volume":"45","author":"Wheat","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1086\/588300","article-title":"Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America","volume":"46","author":"Chapman","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0002-9343(92)90575-V","article-title":"Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group","volume":"93","author":"Dismukes","year":"1992","journal-title":"Am. J. Med."},{"key":"ref_47","unstructured":"Food and Drug Administration (2023, January 18). Vfend (Voriconazole). Full Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021266s032lbl.pdf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/AAC.42.11.3018","article-title":"Organism-dependent fungicidal activities of azoles","volume":"42","author":"Manavathu","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00006454-200203000-00015","article-title":"Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children","volume":"21","author":"Walsh","year":"2002","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1179\/joc.2008.20.1.93","article-title":"Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function","volume":"20","author":"Garcia","year":"2008","journal-title":"J. Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/cir969","article-title":"Administration of voriconazole in patients with renal dysfunction","volume":"54","author":"Neofytos","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1128\/AAC.05841-11","article-title":"Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia","volume":"56","author":"Sobel","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1128\/AAC.01092-06","article-title":"A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations","volume":"51","author":"Mellado","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.fgb.2015.06.001","article-title":"Genotype-phenotype complexity of the TR46\/Y121F\/T289A cyp51A azole resistance mechanism in Aspergillus fumigatus","volume":"82","author":"Snelders","year":"2015","journal-title":"Fungal Genet. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1128\/AAC.00514-12","article-title":"Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus","volume":"56","author":"Tashiro","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Singh, A., Sharma, B., and Mahto, K.K. (2020). High-Frequency Direct Detection of Triazole Resistance in Aspergillus fumigatus from Patients with Chronic Pulmonary Fungal Diseases in India. J. Fungi, 6.","DOI":"10.3390\/jof6020067"},{"key":"ref_58","first-page":"8","article-title":"Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study","volume":"68","author":"Lestrade","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/jac\/dkaa516","article-title":"Do high MICs predict the outcome in invasive fusariosis?","volume":"76","author":"Nucci","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1086\/588844","article-title":"Hallucinations during Voriconazole Therapy","volume":"47","author":"Zonios","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: A systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/cid\/ciu513","article-title":"Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain","volume":"59","author":"Moon","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1182\/blood-2012-01-403030","article-title":"Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole","volume":"120","author":"Gerber","year":"2012","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaad.2018.08.010","article-title":"Voriconazole exposure and risk of cutaneous squamous cell carcinoma among lung or hematopoietic cell transplant patients: A systematic review and meta-analysis","volume":"80","author":"Tang","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: A meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.jinf.2005.08.022","article-title":"The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis","volume":"52","author":"Jain","year":"2006","journal-title":"J. Infect."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"527-e17","DOI":"10.1016\/j.amjmed.2005.11.028","article-title":"Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis","volume":"119","author":"Sambatakou","year":"2006","journal-title":"Am. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s15010-012-0322-x","article-title":"Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: Experience in Japan","volume":"40","author":"Saito","year":"2012","journal-title":"Infection"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s15010-014-0711-4","article-title":"Treatment of chronic pulmonary aspergillosis with voriconazole: Review of a case series","volume":"43","author":"Cucchetto","year":"2015","journal-title":"Infection"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/1469-0691.12409","article-title":"Improvement in the outcome of invasive fusariosis in the last decade","volume":"20","author":"Nucci","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1128\/AAC.01388-07","article-title":"Treatment of scedosporiosis with voriconazole: Clinical experience with 107 patients","volume":"52","author":"Troke","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_75","unstructured":"Food and Drug Administration (2023, January 18). Noxafil (Posaconazole). Full Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.1128\/AAC.03777-14","article-title":"Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis","volume":"58","author":"Dolton","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1128\/AAC.02448-13","article-title":"Posaconazole tablet pharmacokinetics: Lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects","volume":"58","author":"Kraft","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1128\/AAC.05000-14","article-title":"Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation","volume":"59","author":"Kersemaekers","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1128\/AAC.00222-12","article-title":"Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension","volume":"56","author":"Krishna","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/jac\/dks268","article-title":"A new solid oral tablet formulation of posaconazole: A randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers","volume":"67","author":"Krishna","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/myc.12851","article-title":"Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients","volume":"62","author":"DiPippo","year":"2019","journal-title":"Mycoses"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40265-020-01306-y","article-title":"Pharmacokinetics and Pharmacodynamics of Posaconazole","volume":"80","author":"Chen","year":"2020","journal-title":"Drugs"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/jac\/dkq385","article-title":"Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis","volume":"66","author":"Calcagno","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/bmt.2009.17","article-title":"Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis","volume":"44","author":"Reinwald","year":"2009","journal-title":"Bone Marrow Transplant."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/jac\/dkn409","article-title":"Posaconazole concentrations in the central nervous system","volume":"62","author":"Ruping","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_87","first-page":"121","article-title":"In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: Review of the literature","volume":"20","year":"2003","journal-title":"Rev. Iberoam. Micol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/js.2019-00189","article-title":"Posaconazole-Induced Hypertension Due to Inhibition of 11\u03b2-Hydroxylase and 11\u03b2-Hydroxysteroid Dehydrogenase 2","volume":"3","author":"Thompson","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1128\/AAC.05900-11","article-title":"Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug Monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/657306","article-title":"Efficacy and safety of posaconazole for chronic pulmonary aspergillosis","volume":"51","author":"Felton","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/1040841X.2012.711741","article-title":"Mucormycosis treated with posaconazole: Review of 96 case reports","volume":"39","author":"Vehreschild","year":"2013","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1086\/503425","article-title":"Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions","volume":"42","author":"Raad","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_95","unstructured":"Food and Drug Administration (2023, January 18). Cresemba (Isavuconazole). Full Prescribing Information, Available online: https:\/\/wwwaccessdatafdagov\/drugsatfda_docs\/label\/2015\/207500Orig1s000lblpdf2015."},{"key":"ref_96","unstructured":"European Medicines Agency (2023, January 18). Cresemba. Summary of Product Characteristics, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cresemba-epar-product-information_en.pdf."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"572","DOI":"10.5414\/CP202434","article-title":"Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH","volume":"54","author":"Desai","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11046-010-9324-3","article-title":"Isavuconazole: A comprehensive review of spectrum of activity of a new triazole","volume":"170","author":"Thompson","year":"2010","journal-title":"Mycopathologia"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e0123021","DOI":"10.1128\/JCM.01230-21","article-title":"Epidemiology and Antifungal Susceptibilities of Mucoralean Fungi in Clinical Samples from the United States","volume":"59","author":"Badali","year":"2021","journal-title":"J. Clin. Microbiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1128\/AAC.01919-15","article-title":"In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order","volume":"59","author":"Arendrup","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Borman, A.M., Fraser, M., Patterson, Z., Palmer, M.D., and Johnson, E.M. (2021). In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles. J. Fungi, 7.","DOI":"10.3390\/jof7040271"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/jac\/dkx354","article-title":"Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs","volume":"73","author":"Buil","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/JCM.00854-09","article-title":"Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network","volume":"47","author":"Baddley","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1128\/AAC.00383-13","article-title":"Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study)","volume":"57","author":"Mellado","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciaa230","article-title":"Invasive aspergillosis due to Aspergillus section Usti: A multicenter retrospective study","volume":"72","author":"Glampedakis","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e01621-19","DOI":"10.1128\/AAC.01621-19","article-title":"In Vitro Susceptibility of Fusarium to Isavuconazole","volume":"64","author":"Broutin","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e01634-18","DOI":"10.1128\/AAC.01634-18","article-title":"Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials","volume":"63","author":"Andes","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/cpt.620","article-title":"QT Interval Shortening with Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization","volume":"101","author":"Keirns","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1476-5381.2009.00191.x","article-title":"Drug-induced QT interval shortening: Potential harbinger of proarrhythmia and regulatory perspectives","volume":"159","author":"Shah","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cpdd.284","article-title":"Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole with the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults","volume":"6","author":"Groll","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/cpdd.280","article-title":"Pharmacokinetic Interactions between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects","volume":"6","author":"Yamazaki","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: Focus on drugs without a clear recommendation","volume":"26","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/cid\/ciy827","article-title":"Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial","volume":"68","author":"Kullberg","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/mmy\/myaa022","article-title":"Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center","volume":"58","author":"Borman","year":"2020","journal-title":"Med. Mycol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Zurl, C., Waller, M., Schwameis, F., Muhr, T., Bauer, N., Zollner-Schwetz, I., Valentin, T., Meinitzer, A., Ullrich, E., and Wunsch, S. (2020). Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations. J. Fungi, 6.","DOI":"10.3390\/jof6020090"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jac\/dkx423","article-title":"Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: A post hoc analysis of the SECURE trial","volume":"73","author":"Kontoyiannis","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1073\/pnas.1117280109","article-title":"Amphotericin primarily kills yeast by simply binding ergosterol","volume":"109","author":"Gray","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nchembio.1496","article-title":"Amphotericin forms an extramembranous and fungicidal sterol sponge","volume":"10","author":"Anderson","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1128\/AAC.46.3.834-840.2002","article-title":"Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Vincent, B.M., Lancaster, A.K., Scherz-Shouval, R., Whitesell, L., and Lindquist, S. (2013). Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol., 11.","DOI":"10.1371\/journal.pbio.1001692"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jac\/42.4.497","article-title":"In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis","volume":"42","author":"Kofler","year":"1998","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e02651-16","DOI":"10.1128\/AAC.02651-16","article-title":"Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies","volume":"61","author":"Stanzani","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1001\/archinte.1988.00380110049010","article-title":"Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation","volume":"148","author":"Branch","year":"1988","journal-title":"Arch. Intern. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/jac\/dkp140","article-title":"Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation","volume":"64","author":"Gershkovich","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1128\/AAC.00241-06","article-title":"Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations","volume":"50","author":"Groll","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/cid\/cis290","article-title":"Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis","volume":"54","author":"Mistro","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1086\/431586","article-title":"The hepatotoxicity of antifungal medications in bone marrow transplant recipients","volume":"41","author":"Fischer","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/cid\/cis972","article-title":"The safety of amphotericin B lipid complex in patients with prior severe intolerance to liposomal amphotericin B","volume":"56","author":"Farmakiotis","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","article-title":"Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007","volume":"17","author":"Skiada","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1179\/joc.2009.21.3.322","article-title":"Zygomycosis in Italy: A survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology)","volume":"21","author":"Pagano","year":"2009","journal-title":"J. Chemother."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/jac\/dkv236","article-title":"Prospective pilot study of high-dose (10 mg\/kg\/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis","volume":"70","author":"Lanternier","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1128\/AAC.01488-07","article-title":"Comparison of lipid amphotericin B preparations in treating murine zygomycosis","volume":"52","author":"Ibrahim","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1710922","article-title":"Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa","volume":"378","author":"Molloy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa1110404","article-title":"Combination Antifungal Therapy for Cryptococcal Meningitis","volume":"368","author":"Day","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(04)16301-0","article-title":"Combination antifungal therapies for HIV-associated cryptococcal meningitis: A randomised trial","volume":"363","author":"Brouwer","year":"2004","journal-title":"Lancet"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa2111904","article-title":"Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis","volume":"386","author":"Jarvis","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_143","unstructured":"World Health Organization (2023, January 18). Guidelines for Diagnosing, Preventing and Managing Cryptococcal Disease among Adults, Adolescents and Children Living with HIV, Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240052178."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"511","DOI":"10.7326\/0003-4819-75-4-511","article-title":"Disseminated histoplasmosis: Results of long-term follow-up. A center for disease control cooperative mycoses study","volume":"75","author":"Sarosi","year":"1971","journal-title":"Ann. Intern. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-137-2-200207160-00008","article-title":"Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS","volume":"137","author":"Johnson","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"S401","DOI":"10.1086\/429331","article-title":"Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex","volume":"40","author":"Perfect","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1128\/AAC.46.9.3001-3012.2002","article-title":"The Antifungal Echinocandin Caspofungin Acetate Kills Growing Cells of Aspergillus fumigatus In Vitro","volume":"46","author":"Bowman","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1080\/13693780600981684","article-title":"Understanding the microbiology of the Aspergillus cell wall and the efficacy of caspofungin","volume":"44","author":"Douglas","year":"2006","journal-title":"Med. Mycol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): A multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2022","journal-title":"Lancet"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: Non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/1469-0691.12041","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: Adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)","volume":"18","author":"Ullmann","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_154","unstructured":"Food and Drug Administration (2001). Cancidas (Caspofungin), Full Prescribing Information."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/jac\/dky189","article-title":"Caspofungin dosage adjustments are not required for patients with Child-Pugh B or C cirrhosis","volume":"73","author":"Gustot","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1093\/jac\/dkv235","article-title":"Switching to anidulafungin from caspofungin in cancer patients in the setting of liver dysfunction is associated with improvement of liver function tests","volume":"70","author":"Jung","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dkp355","article-title":"An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients","volume":"64","author":"Viscoli","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/bmt.2009.334","article-title":"Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: An European Organisation for Research and Treatment of Cancer study","volume":"45","author":"Herbrecht","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1128\/AAC.05134-11","article-title":"Phase II dose escalation study of caspofungin for invasive Aspergillosis","volume":"55","author":"Cornely","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jinf.2006.03.003","article-title":"Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis","volume":"53","author":"Denning","year":"2006","journal-title":"J. Infect."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s10096-010-1013-0","article-title":"Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort","volume":"29","author":"Hiemenz","year":"2010","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: A randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/cid\/cit393","article-title":"The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis","volume":"57","author":"Fisher","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1086\/528714","article-title":"Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: Clinical and research implications","volume":"46","author":"Miceli","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Yashphe, E.L., Ram, R., Avivi, I., and Ben-Ami, R. (2021). Predictors of Early and Late Mortality for Patients with Hematologic Malignancy and Invasive Mold Disease. J. Fungi, 7.","DOI":"10.3390\/jof7090697"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1002\/cncr.22348","article-title":"Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis","volume":"107","author":"Maertens","year":"2006","journal-title":"Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/423380","article-title":"Combination antifungal therapy for invasive aspergillosis","volume":"39","author":"Marr","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jinf.2010.08.005","article-title":"Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: A multicenter trial in Japan","volume":"61","author":"Kohno","year":"2010","journal-title":"J. Infect."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10096-012-1754-z","article-title":"A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis","volume":"32","author":"Kohno","year":"2013","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/thoraxjnl-2013-203988","article-title":"Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis","volume":"69","author":"Keir","year":"2014","journal-title":"Thorax"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Gintjee, T.J., Donnelley, M.A., and Thompson, G.R. (2020). Aspiring Antifungals: Review of Current Antifungal Pipeline Developments. J. Fungi, 6.","DOI":"10.3390\/jof6010028"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/cid\/ciab1070","article-title":"Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective","volume":"75","author":"Lamoth","year":"2022","journal-title":"Clin. Infect. Dis."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/9\/2\/144\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:13:04Z","timestamp":1760119984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/9\/2\/144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,21]]},"references-count":172,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["jof9020144"],"URL":"https:\/\/doi.org\/10.3390\/jof9020144","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,21]]}}}